nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—UGT2B7—Epirubicin—uterine cancer	0.269	0.568	CbGbCtD
Dabigatran etexilate—ABCB1—Progesterone—uterine cancer	0.0803	0.17	CbGbCtD
Dabigatran etexilate—ABCB1—Dactinomycin—uterine cancer	0.0637	0.134	CbGbCtD
Dabigatran etexilate—F2—posterior vena cava—uterine cancer	0.0553	0.295	CbGeAlD
Dabigatran etexilate—ABCB1—Etoposide—uterine cancer	0.0359	0.0759	CbGbCtD
Dabigatran etexilate—ABCB1—Doxorubicin—uterine cancer	0.0245	0.0518	CbGbCtD
Dabigatran etexilate—F2—artery—uterine cancer	0.00993	0.0531	CbGeAlD
Dabigatran etexilate—CES2—myometrium—uterine cancer	0.00535	0.0286	CbGeAlD
Dabigatran etexilate—UGT2B15—female reproductive system—uterine cancer	0.00511	0.0273	CbGeAlD
Dabigatran etexilate—UGT1A9—renal system—uterine cancer	0.00483	0.0258	CbGeAlD
Dabigatran etexilate—NQO2—myometrium—uterine cancer	0.00478	0.0256	CbGeAlD
Dabigatran etexilate—CES2—uterine cervix—uterine cancer	0.00416	0.0223	CbGeAlD
Dabigatran etexilate—CES2—smooth muscle tissue—uterine cancer	0.00405	0.0216	CbGeAlD
Dabigatran etexilate—CES2—decidua—uterine cancer	0.00397	0.0212	CbGeAlD
Dabigatran etexilate—CES2—Fluoropyrimidine Activity—RRM2—uterine cancer	0.00395	0.0797	CbGpPWpGaD
Dabigatran etexilate—CES2—renal system—uterine cancer	0.0039	0.0208	CbGeAlD
Dabigatran etexilate—UGT2B7—renal system—uterine cancer	0.0039	0.0208	CbGeAlD
Dabigatran etexilate—F2—epithelium—uterine cancer	0.00377	0.0201	CbGeAlD
Dabigatran etexilate—CES2—endometrium—uterine cancer	0.00377	0.0201	CbGeAlD
Dabigatran etexilate—NQO2—uterine cervix—uterine cancer	0.00372	0.0199	CbGeAlD
Dabigatran etexilate—CES2—mammalian vulva—uterine cancer	0.00364	0.0195	CbGeAlD
Dabigatran etexilate—NQO2—decidua—uterine cancer	0.00354	0.0189	CbGeAlD
Dabigatran etexilate—F2—renal system—uterine cancer	0.00349	0.0187	CbGeAlD
Dabigatran etexilate—NQO2—renal system—uterine cancer	0.00348	0.0186	CbGeAlD
Dabigatran etexilate—CES2—uterus—uterine cancer	0.00347	0.0185	CbGeAlD
Dabigatran etexilate—NQO2—endometrium—uterine cancer	0.00337	0.018	CbGeAlD
Dabigatran etexilate—NQO2—mammalian vulva—uterine cancer	0.00326	0.0174	CbGeAlD
Dabigatran etexilate—UGT2B7—female reproductive system—uterine cancer	0.00312	0.0167	CbGeAlD
Dabigatran etexilate—CES2—female reproductive system—uterine cancer	0.00312	0.0167	CbGeAlD
Dabigatran etexilate—NQO2—uterus—uterine cancer	0.0031	0.0166	CbGeAlD
Dabigatran etexilate—CES2—female gonad—uterine cancer	0.00284	0.0152	CbGeAlD
Dabigatran etexilate—CES2—vagina—uterine cancer	0.00282	0.0151	CbGeAlD
Dabigatran etexilate—F2—female reproductive system—uterine cancer	0.0028	0.015	CbGeAlD
Dabigatran etexilate—NQO2—female reproductive system—uterine cancer	0.00279	0.0149	CbGeAlD
Dabigatran etexilate—CES1—female reproductive system—uterine cancer	0.00257	0.0137	CbGeAlD
Dabigatran etexilate—F2—female gonad—uterine cancer	0.00255	0.0136	CbGeAlD
Dabigatran etexilate—NQO2—female gonad—uterine cancer	0.00254	0.0136	CbGeAlD
Dabigatran etexilate—NQO2—vagina—uterine cancer	0.00252	0.0135	CbGeAlD
Dabigatran etexilate—CES1—female gonad—uterine cancer	0.00234	0.0125	CbGeAlD
Dabigatran etexilate—CES1—Fluoropyrimidine Activity—RRM2—uterine cancer	0.00233	0.0469	CbGpPWpGaD
Dabigatran etexilate—CES2—E2F transcription factor network—RRM2—uterine cancer	0.00209	0.0422	CbGpPWpGaD
Dabigatran etexilate—CES2—Fluoropyrimidine Activity—MTHFR—uterine cancer	0.002	0.0403	CbGpPWpGaD
Dabigatran etexilate—CES2—lymph node—uterine cancer	0.00182	0.00975	CbGeAlD
Dabigatran etexilate—NQO2—lymph node—uterine cancer	0.00163	0.00872	CbGeAlD
Dabigatran etexilate—CES1—lymph node—uterine cancer	0.0015	0.00803	CbGeAlD
Dabigatran etexilate—CES2—NRF2 pathway—NFE2L2—uterine cancer	0.00124	0.025	CbGpPWpGaD
Dabigatran etexilate—CES1—E2F transcription factor network—RRM2—uterine cancer	0.00123	0.0249	CbGpPWpGaD
Dabigatran etexilate—CES2—NRF2 pathway—GPX3—uterine cancer	0.00118	0.0239	CbGpPWpGaD
Dabigatran etexilate—CES1—Fluoropyrimidine Activity—MTHFR—uterine cancer	0.00118	0.0237	CbGpPWpGaD
Dabigatran etexilate—ABCB1—myometrium—uterine cancer	0.00103	0.00552	CbGeAlD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—NFE2L2—uterine cancer	0.00086	0.0173	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—GPX3—uterine cancer	0.000811	0.0164	CbGpPWpGaD
Dabigatran etexilate—ABCB1—epithelium—uterine cancer	0.00081	0.00433	CbGeAlD
Dabigatran etexilate—ABCB1—uterine cervix—uterine cancer	0.000803	0.00429	CbGeAlD
Dabigatran etexilate—ABCB1—decidua—uterine cancer	0.000765	0.00409	CbGeAlD
Dabigatran etexilate—CES2—Fluoropyrimidine Activity—TP53—uterine cancer	0.000758	0.0153	CbGpPWpGaD
Dabigatran etexilate—ABCB1—renal system—uterine cancer	0.000751	0.00402	CbGeAlD
Dabigatran etexilate—F2—IL1 and megakaryotyces in obesity—CCL2—uterine cancer	0.000732	0.0148	CbGpPWpGaD
Dabigatran etexilate—CES1—NRF2 pathway—NFE2L2—uterine cancer	0.000732	0.0148	CbGpPWpGaD
Dabigatran etexilate—Hyperbilirubinaemia—Epirubicin—uterine cancer	0.000728	0.00251	CcSEcCtD
Dabigatran etexilate—ABCB1—endometrium—uterine cancer	0.000726	0.00388	CbGeAlD
Dabigatran etexilate—Dyspepsia—Progesterone—uterine cancer	0.000725	0.0025	CcSEcCtD
Dabigatran etexilate—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.000725	0.0025	CcSEcCtD
Dabigatran etexilate—CES2—E2F transcription factor network—CDKN2A—uterine cancer	0.000722	0.0146	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Biological oxidations—CYP11A1—uterine cancer	0.000717	0.0145	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal disorder—Progesterone—uterine cancer	0.000711	0.00246	CcSEcCtD
Dabigatran etexilate—ABCB1—ABC-family proteins mediated transport—ABCC9—uterine cancer	0.000711	0.0143	CbGpPWpGaD
Dabigatran etexilate—Fatigue—Progesterone—uterine cancer	0.00071	0.00245	CcSEcCtD
Dabigatran etexilate—Constipation—Progesterone—uterine cancer	0.000704	0.00243	CcSEcCtD
Dabigatran etexilate—ABCB1—mammalian vulva—uterine cancer	0.000703	0.00376	CbGeAlD
Dabigatran etexilate—Blood bilirubin increased—Epirubicin—uterine cancer	0.0007	0.00242	CcSEcCtD
Dabigatran etexilate—CES1—NRF2 pathway—GPX3—uterine cancer	0.000698	0.0141	CbGpPWpGaD
Dabigatran etexilate—Hypotension—Medroxyprogesterone Acetate—uterine cancer	0.000697	0.00241	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Medroxyprogesterone Acetate—uterine cancer	0.00068	0.00235	CcSEcCtD
Dabigatran etexilate—Bone disorder—Doxorubicin—uterine cancer	0.000678	0.00234	CcSEcCtD
Dabigatran etexilate—Rectal haemorrhage—Doxorubicin—uterine cancer	0.000678	0.00234	CcSEcCtD
Dabigatran etexilate—Hyperbilirubinaemia—Doxorubicin—uterine cancer	0.000674	0.00233	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Progesterone—uterine cancer	0.000674	0.00233	CcSEcCtD
Dabigatran etexilate—Musculoskeletal pain—Epirubicin—uterine cancer	0.00067	0.00231	CcSEcCtD
Dabigatran etexilate—ABCB1—uterus—uterine cancer	0.000669	0.00358	CbGeAlD
Dabigatran etexilate—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.000665	0.0023	CcSEcCtD
Dabigatran etexilate—Pneumonia—Etoposide—uterine cancer	0.000665	0.00229	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Etoposide—uterine cancer	0.000661	0.00228	CcSEcCtD
Dabigatran etexilate—Infestation—Etoposide—uterine cancer	0.000661	0.00228	CcSEcCtD
Dabigatran etexilate—Anaemia—Dactinomycin—uterine cancer	0.000659	0.00228	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.000657	0.00227	CcSEcCtD
Dabigatran etexilate—Urticaria—Progesterone—uterine cancer	0.000654	0.00226	CcSEcCtD
Dabigatran etexilate—Acute coronary syndrome—Etoposide—uterine cancer	0.000651	0.00225	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Progesterone—uterine cancer	0.000651	0.00225	CcSEcCtD
Dabigatran etexilate—Blood bilirubin increased—Doxorubicin—uterine cancer	0.000648	0.00224	CcSEcCtD
Dabigatran etexilate—Myocardial infarction—Etoposide—uterine cancer	0.000648	0.00224	CcSEcCtD
Dabigatran etexilate—F2—Selenium Micronutrient Network—GPX3—uterine cancer	0.000644	0.013	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000644	0.00222	CcSEcCtD
Dabigatran etexilate—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.000644	0.00222	CcSEcCtD
Dabigatran etexilate—CES2—E2F transcription factor network—CDKN1B—uterine cancer	0.00064	0.0129	CbGpPWpGaD
Dabigatran etexilate—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.000638	0.0022	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Etoposide—uterine cancer	0.000625	0.00216	CcSEcCtD
Dabigatran etexilate—Musculoskeletal pain—Doxorubicin—uterine cancer	0.00062	0.00214	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.00061	0.00211	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Progesterone—uterine cancer	0.000607	0.0021	CcSEcCtD
Dabigatran etexilate—Oesophagitis—Epirubicin—uterine cancer	0.000605	0.00209	CcSEcCtD
Dabigatran etexilate—ABCB1—female reproductive system—uterine cancer	0.000602	0.00322	CbGeAlD
Dabigatran etexilate—Ecchymosis—Epirubicin—uterine cancer	0.000599	0.00207	CcSEcCtD
Dabigatran etexilate—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.000593	0.00205	CcSEcCtD
Dabigatran etexilate—Asthenia—Progesterone—uterine cancer	0.000591	0.00204	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.00059	0.00204	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Etoposide—uterine cancer	0.000586	0.00202	CcSEcCtD
Dabigatran etexilate—Pruritus—Progesterone—uterine cancer	0.000583	0.00201	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Etoposide—uterine cancer	0.000581	0.00201	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metapathway biotransformation—AKR1B10—uterine cancer	0.000579	0.0117	CbGpPWpGaD
Dabigatran etexilate—Infection—Dactinomycin—uterine cancer	0.000578	0.002	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Dactinomycin—uterine cancer	0.00057	0.00197	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Progesterone—uterine cancer	0.000564	0.00195	CcSEcCtD
Dabigatran etexilate—CES2—E2F transcription factor network—EP300—uterine cancer	0.000562	0.0113	CbGpPWpGaD
Dabigatran etexilate—Oesophagitis—Doxorubicin—uterine cancer	0.00056	0.00193	CcSEcCtD
Dabigatran etexilate—Ecchymosis—Doxorubicin—uterine cancer	0.000554	0.00191	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Etoposide—uterine cancer	0.00055	0.0019	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.00055	0.0019	CcSEcCtD
Dabigatran etexilate—Hepatic function abnormal—Epirubicin—uterine cancer	0.00055	0.0019	CcSEcCtD
Dabigatran etexilate—ABCB1—female gonad—uterine cancer	0.000548	0.00293	CbGeAlD
Dabigatran etexilate—Dizziness—Progesterone—uterine cancer	0.000545	0.00188	CcSEcCtD
Dabigatran etexilate—ABCB1—vagina—uterine cancer	0.000544	0.00291	CbGeAlD
Dabigatran etexilate—UGT2B7—Metapathway biotransformation—AKR1B1—uterine cancer	0.000538	0.0109	CbGpPWpGaD
Dabigatran etexilate—Angiopathy—Etoposide—uterine cancer	0.000538	0.00186	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Etoposide—uterine cancer	0.000536	0.00185	CcSEcCtD
Dabigatran etexilate—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000536	0.00185	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Etoposide—uterine cancer	0.000535	0.00185	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.00053	0.00183	CcSEcCtD
Dabigatran etexilate—Cardiac failure congestive—Epirubicin—uterine cancer	0.00053	0.00183	CcSEcCtD
Dabigatran etexilate—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000528	0.00182	CcSEcCtD
Dabigatran etexilate—UGT2B15—Biological oxidations—CYP19A1—uterine cancer	0.000527	0.0106	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Progesterone—uterine cancer	0.000524	0.00181	CcSEcCtD
Dabigatran etexilate—Rash—Progesterone—uterine cancer	0.000519	0.00179	CcSEcCtD
Dabigatran etexilate—Dermatitis—Progesterone—uterine cancer	0.000519	0.00179	CcSEcCtD
Dabigatran etexilate—Headache—Progesterone—uterine cancer	0.000516	0.00178	CcSEcCtD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—MTHFR—uterine cancer	0.000512	0.0103	CbGpPWpGaD
Dabigatran etexilate—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000511	0.00176	CcSEcCtD
Dabigatran etexilate—Hepatic function abnormal—Doxorubicin—uterine cancer	0.000509	0.00176	CcSEcCtD
Dabigatran etexilate—Fatigue—Dactinomycin—uterine cancer	0.000502	0.00173	CcSEcCtD
Dabigatran etexilate—Back pain—Etoposide—uterine cancer	0.000499	0.00172	CcSEcCtD
Dabigatran etexilate—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000494	0.0017	CcSEcCtD
Dabigatran etexilate—Cardiac failure—Epirubicin—uterine cancer	0.000492	0.0017	CcSEcCtD
Dabigatran etexilate—Cardiac failure congestive—Doxorubicin—uterine cancer	0.00049	0.00169	CcSEcCtD
Dabigatran etexilate—Nausea—Progesterone—uterine cancer	0.000489	0.00169	CcSEcCtD
Dabigatran etexilate—Osteoarthritis—Epirubicin—uterine cancer	0.000481	0.00166	CcSEcCtD
Dabigatran etexilate—Gastrointestinal haemorrhage—Epirubicin—uterine cancer	0.000481	0.00166	CcSEcCtD
Dabigatran etexilate—Pain in extremity—Epirubicin—uterine cancer	0.000481	0.00166	CcSEcCtD
Dabigatran etexilate—Anaemia—Etoposide—uterine cancer	0.000477	0.00165	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000476	0.00164	CcSEcCtD
Dabigatran etexilate—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000475	0.00164	CcSEcCtD
Dabigatran etexilate—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000471	0.00162	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metapathway biotransformation—AKR1B10—uterine cancer	0.00047	0.00948	CbGpPWpGaD
Dabigatran etexilate—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.00047	0.00162	CcSEcCtD
Dabigatran etexilate—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000468	0.00161	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Dactinomycin—uterine cancer	0.00046	0.00159	CcSEcCtD
Dabigatran etexilate—Cardiac failure—Doxorubicin—uterine cancer	0.000456	0.00157	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Etoposide—uterine cancer	0.000454	0.00157	CcSEcCtD
Dabigatran etexilate—Cough—Etoposide—uterine cancer	0.000451	0.00156	CcSEcCtD
Dabigatran etexilate—CES1—Fluoropyrimidine Activity—TP53—uterine cancer	0.000447	0.00901	CbGpPWpGaD
Dabigatran etexilate—Hypertension—Etoposide—uterine cancer	0.000446	0.00154	CcSEcCtD
Dabigatran etexilate—Pain in extremity—Doxorubicin—uterine cancer	0.000445	0.00154	CcSEcCtD
Dabigatran etexilate—Osteoarthritis—Doxorubicin—uterine cancer	0.000445	0.00154	CcSEcCtD
Dabigatran etexilate—Gastrointestinal haemorrhage—Doxorubicin—uterine cancer	0.000445	0.00154	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Epirubicin—uterine cancer	0.000444	0.00153	CcSEcCtD
Dabigatran etexilate—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000443	0.00153	CcSEcCtD
Dabigatran etexilate—Chest pain—Etoposide—uterine cancer	0.00044	0.00152	CcSEcCtD
Dabigatran etexilate—Abdominal pain upper—Epirubicin—uterine cancer	0.000439	0.00152	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metapathway biotransformation—AKR1B1—uterine cancer	0.000437	0.00882	CbGpPWpGaD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000437	0.00151	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Epirubicin—uterine cancer	0.000433	0.00149	CcSEcCtD
Dabigatran etexilate—Nasopharyngitis—Epirubicin—uterine cancer	0.00043	0.00148	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Dactinomycin—uterine cancer	0.000429	0.00148	CcSEcCtD
Dabigatran etexilate—CES1—E2F transcription factor network—CDKN2A—uterine cancer	0.000426	0.00858	CbGpPWpGaD
Dabigatran etexilate—Gastritis—Epirubicin—uterine cancer	0.000425	0.00147	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.000424	0.00146	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Etoposide—uterine cancer	0.000421	0.00145	CcSEcCtD
Dabigatran etexilate—UGT2B7—NRF2 pathway—NFE2L2—uterine cancer	0.00042	0.00847	CbGpPWpGaD
Dabigatran etexilate—Infection—Etoposide—uterine cancer	0.000419	0.00145	CcSEcCtD
Dabigatran etexilate—Asthenia—Dactinomycin—uterine cancer	0.000418	0.00144	CcSEcCtD
Dabigatran etexilate—F2—Folate Metabolism—MTHFR—uterine cancer	0.000416	0.0084	CbGpPWpGaD
Dabigatran etexilate—Dysphagia—Epirubicin—uterine cancer	0.000415	0.00143	CcSEcCtD
Dabigatran etexilate—Influenza—Epirubicin—uterine cancer	0.000415	0.00143	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Etoposide—uterine cancer	0.000413	0.00142	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Doxorubicin—uterine cancer	0.000411	0.00142	CcSEcCtD
Dabigatran etexilate—Skin disorder—Etoposide—uterine cancer	0.000409	0.00141	CcSEcCtD
Dabigatran etexilate—Abdominal pain upper—Doxorubicin—uterine cancer	0.000406	0.0014	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Epirubicin—uterine cancer	0.000405	0.0014	CcSEcCtD
Dabigatran etexilate—UGT2B7—NRF2 pathway—GPX3—uterine cancer	0.000401	0.00808	CbGpPWpGaD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—CCL2—uterine cancer	0.000401	0.00808	CbGpPWpGaD
Dabigatran etexilate—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.0004	0.00138	CcSEcCtD
Dabigatran etexilate—Bronchitis—Epirubicin—uterine cancer	0.000399	0.00138	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Dactinomycin—uterine cancer	0.000398	0.00138	CcSEcCtD
Dabigatran etexilate—Nasopharyngitis—Doxorubicin—uterine cancer	0.000398	0.00137	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metapathway biotransformation—AKR1C1—uterine cancer	0.000395	0.00796	CbGpPWpGaD
Dabigatran etexilate—Hypotension—Etoposide—uterine cancer	0.000394	0.00136	CcSEcCtD
Dabigatran etexilate—Gastritis—Doxorubicin—uterine cancer	0.000394	0.00136	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000392	0.00135	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000386	0.00133	CcSEcCtD
Dabigatran etexilate—Dysphagia—Doxorubicin—uterine cancer	0.000384	0.00133	CcSEcCtD
Dabigatran etexilate—Influenza—Doxorubicin—uterine cancer	0.000384	0.00133	CcSEcCtD
Dabigatran etexilate—CES1—E2F transcription factor network—CDKN1B—uterine cancer	0.000377	0.0076	CbGpPWpGaD
Dabigatran etexilate—Dyspnoea—Etoposide—uterine cancer	0.000376	0.0013	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Doxorubicin—uterine cancer	0.000374	0.00129	CcSEcCtD
Dabigatran etexilate—Pneumonia—Epirubicin—uterine cancer	0.000373	0.00129	CcSEcCtD
Dabigatran etexilate—Infestation—Epirubicin—uterine cancer	0.00037	0.00128	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Epirubicin—uterine cancer	0.00037	0.00128	CcSEcCtD
Dabigatran etexilate—Vomiting—Dactinomycin—uterine cancer	0.00037	0.00128	CcSEcCtD
Dabigatran etexilate—Bronchitis—Doxorubicin—uterine cancer	0.00037	0.00128	CcSEcCtD
Dabigatran etexilate—F2—IL1 and megakaryotyces in obesity—PIK3CA—uterine cancer	0.000367	0.0074	CbGpPWpGaD
Dabigatran etexilate—Rash—Dactinomycin—uterine cancer	0.000367	0.00127	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Etoposide—uterine cancer	0.000364	0.00126	CcSEcCtD
Dabigatran etexilate—Fatigue—Etoposide—uterine cancer	0.000363	0.00125	CcSEcCtD
Dabigatran etexilate—Constipation—Etoposide—uterine cancer	0.00036	0.00124	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Epirubicin—uterine cancer	0.00036	0.00124	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000357	0.00123	CcSEcCtD
Dabigatran etexilate—F2—Metabolism of proteins—TSPYL2—uterine cancer	0.000354	0.00714	CbGpPWpGaD
Dabigatran etexilate—Haematuria—Epirubicin—uterine cancer	0.000353	0.00122	CcSEcCtD
Dabigatran etexilate—ABCB1—lymph node—uterine cancer	0.000352	0.00188	CbGeAlD
Dabigatran etexilate—Hepatobiliary disease—Epirubicin—uterine cancer	0.00035	0.00121	CcSEcCtD
Dabigatran etexilate—Epistaxis—Epirubicin—uterine cancer	0.000349	0.00121	CcSEcCtD
Dabigatran etexilate—Sinusitis—Epirubicin—uterine cancer	0.000347	0.0012	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metapathway biotransformation—GPX3—uterine cancer	0.000347	0.00699	CbGpPWpGaD
Dabigatran etexilate—Nausea—Dactinomycin—uterine cancer	0.000346	0.00119	CcSEcCtD
Dabigatran etexilate—Pneumonia—Doxorubicin—uterine cancer	0.000345	0.00119	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Etoposide—uterine cancer	0.000345	0.00119	CcSEcCtD
Dabigatran etexilate—Infestation—Doxorubicin—uterine cancer	0.000343	0.00118	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Doxorubicin—uterine cancer	0.000343	0.00118	CcSEcCtD
Dabigatran etexilate—UGT1A9—NRF2 pathway—NFE2L2—uterine cancer	0.000341	0.00688	CbGpPWpGaD
Dabigatran etexilate—Urticaria—Etoposide—uterine cancer	0.000335	0.00116	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Epirubicin—uterine cancer	0.000334	0.00115	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Etoposide—uterine cancer	0.000333	0.00115	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Doxorubicin—uterine cancer	0.000333	0.00115	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Epirubicin—uterine cancer	0.000332	0.00115	CcSEcCtD
Dabigatran etexilate—CES1—E2F transcription factor network—EP300—uterine cancer	0.000331	0.00667	CbGpPWpGaD
Dabigatran etexilate—F2—Selenium Micronutrient Network—MTHFR—uterine cancer	0.000331	0.00667	CbGpPWpGaD
Dabigatran etexilate—Urinary tract disorder—Epirubicin—uterine cancer	0.000328	0.00113	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Epirubicin—uterine cancer	0.000328	0.00113	CcSEcCtD
Dabigatran etexilate—Haematuria—Doxorubicin—uterine cancer	0.000327	0.00113	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Epirubicin—uterine cancer	0.000327	0.00113	CcSEcCtD
Dabigatran etexilate—UGT2B7—Biological oxidations—CYP11A1—uterine cancer	0.000326	0.00658	CbGpPWpGaD
Dabigatran etexilate—Urethral disorder—Epirubicin—uterine cancer	0.000326	0.00113	CcSEcCtD
Dabigatran etexilate—F2—Folate Metabolism—CCL2—uterine cancer	0.000326	0.00657	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—NRF2 pathway—GPX3—uterine cancer	0.000326	0.00657	CbGpPWpGaD
Dabigatran etexilate—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000324	0.00112	CcSEcCtD
Dabigatran etexilate—Epistaxis—Doxorubicin—uterine cancer	0.000323	0.00112	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metapathway biotransformation—CYP11A1—uterine cancer	0.000322	0.00649	CbGpPWpGaD
Dabigatran etexilate—Sinusitis—Doxorubicin—uterine cancer	0.000321	0.00111	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metapathway biotransformation—AKR1C1—uterine cancer	0.000321	0.00647	CbGpPWpGaD
Dabigatran etexilate—Hypersensitivity—Etoposide—uterine cancer	0.00031	0.00107	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Doxorubicin—uterine cancer	0.000309	0.00107	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Epirubicin—uterine cancer	0.000309	0.00107	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Doxorubicin—uterine cancer	0.000308	0.00106	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metapathway biotransformation—AKR1C3—uterine cancer	0.000304	0.00613	CbGpPWpGaD
Dabigatran etexilate—Urinary tract disorder—Doxorubicin—uterine cancer	0.000304	0.00105	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Doxorubicin—uterine cancer	0.000303	0.00105	CcSEcCtD
Dabigatran etexilate—Asthenia—Etoposide—uterine cancer	0.000302	0.00104	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Doxorubicin—uterine cancer	0.000302	0.00104	CcSEcCtD
Dabigatran etexilate—Angiopathy—Epirubicin—uterine cancer	0.000302	0.00104	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Doxorubicin—uterine cancer	0.000302	0.00104	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Epirubicin—uterine cancer	0.0003	0.00104	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Epirubicin—uterine cancer	0.0003	0.00103	CcSEcCtD
Dabigatran etexilate—Pruritus—Etoposide—uterine cancer	0.000298	0.00103	CcSEcCtD
Dabigatran etexilate—Malnutrition—Epirubicin—uterine cancer	0.000289	0.000999	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Etoposide—uterine cancer	0.000288	0.000995	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Doxorubicin—uterine cancer	0.000285	0.000986	CcSEcCtD
Dabigatran etexilate—Flatulence—Epirubicin—uterine cancer	0.000285	0.000985	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—NDUFB11—uterine cancer	0.000283	0.00571	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—SRD5A2—uterine cancer	0.000283	0.00571	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metapathway biotransformation—GPX3—uterine cancer	0.000282	0.00568	CbGpPWpGaD
Dabigatran etexilate—Back pain—Epirubicin—uterine cancer	0.00028	0.000966	CcSEcCtD
Dabigatran etexilate—Angiopathy—Doxorubicin—uterine cancer	0.000279	0.000964	CcSEcCtD
Dabigatran etexilate—Dizziness—Etoposide—uterine cancer	0.000279	0.000962	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Doxorubicin—uterine cancer	0.000278	0.000959	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Doxorubicin—uterine cancer	0.000277	0.000957	CcSEcCtD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MAP3K4—uterine cancer	0.000273	0.0055	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Etoposide—uterine cancer	0.000268	0.000925	CcSEcCtD
Dabigatran etexilate—Malnutrition—Doxorubicin—uterine cancer	0.000268	0.000924	CcSEcCtD
Dabigatran etexilate—Anaemia—Epirubicin—uterine cancer	0.000267	0.000923	CcSEcCtD
Dabigatran etexilate—Rash—Etoposide—uterine cancer	0.000266	0.000917	CcSEcCtD
Dabigatran etexilate—Dermatitis—Etoposide—uterine cancer	0.000265	0.000916	CcSEcCtD
Dabigatran etexilate—UGT1A9—Biological oxidations—CYP11A1—uterine cancer	0.000265	0.00535	CbGpPWpGaD
Dabigatran etexilate—Headache—Etoposide—uterine cancer	0.000264	0.000911	CcSEcCtD
Dabigatran etexilate—Flatulence—Doxorubicin—uterine cancer	0.000264	0.000911	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metapathway biotransformation—CYP11A1—uterine cancer	0.000262	0.00528	CbGpPWpGaD
Dabigatran etexilate—Syncope—Epirubicin—uterine cancer	0.00026	0.000896	CcSEcCtD
Dabigatran etexilate—Back pain—Doxorubicin—uterine cancer	0.000259	0.000894	CcSEcCtD
Dabigatran etexilate—F2—Selenium Micronutrient Network—CCL2—uterine cancer	0.000259	0.00522	CbGpPWpGaD
Dabigatran etexilate—Palpitations—Epirubicin—uterine cancer	0.000256	0.000883	CcSEcCtD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—CDKN1B—uterine cancer	0.000255	0.00513	CbGpPWpGaD
Dabigatran etexilate—Loss of consciousness—Epirubicin—uterine cancer	0.000254	0.000878	CcSEcCtD
Dabigatran etexilate—Cough—Epirubicin—uterine cancer	0.000253	0.000872	CcSEcCtD
Dabigatran etexilate—Nausea—Etoposide—uterine cancer	0.00025	0.000864	CcSEcCtD
Dabigatran etexilate—Hypertension—Epirubicin—uterine cancer	0.00025	0.000863	CcSEcCtD
Dabigatran etexilate—Anaemia—Doxorubicin—uterine cancer	0.000248	0.000854	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metapathway biotransformation—AKR1C3—uterine cancer	0.000247	0.00498	CbGpPWpGaD
Dabigatran etexilate—Arthralgia—Epirubicin—uterine cancer	0.000246	0.000851	CcSEcCtD
Dabigatran etexilate—Chest pain—Epirubicin—uterine cancer	0.000246	0.000851	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000245	0.000845	CcSEcCtD
Dabigatran etexilate—UGT2B7—Biological oxidations—CYP19A1—uterine cancer	0.00024	0.00484	CbGpPWpGaD
Dabigatran etexilate—Syncope—Doxorubicin—uterine cancer	0.00024	0.000829	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metapathway biotransformation—CYP19A1—uterine cancer	0.000237	0.00478	CbGpPWpGaD
Dabigatran etexilate—Palpitations—Doxorubicin—uterine cancer	0.000237	0.000817	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Epirubicin—uterine cancer	0.000236	0.000815	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.000236	0.00475	CbGpPWpGaD
Dabigatran etexilate—Loss of consciousness—Doxorubicin—uterine cancer	0.000235	0.000813	CcSEcCtD
Dabigatran etexilate—Infection—Epirubicin—uterine cancer	0.000235	0.00081	CcSEcCtD
Dabigatran etexilate—Cough—Doxorubicin—uterine cancer	0.000234	0.000807	CcSEcCtD
Dabigatran etexilate—Shock—Epirubicin—uterine cancer	0.000232	0.000802	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Epirubicin—uterine cancer	0.000232	0.0008	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Epirubicin—uterine cancer	0.000231	0.000798	CcSEcCtD
Dabigatran etexilate—Hypertension—Doxorubicin—uterine cancer	0.000231	0.000798	CcSEcCtD
Dabigatran etexilate—F2—PAR1-mediated thrombin signaling events—PIK3CA—uterine cancer	0.00023	0.00464	CbGpPWpGaD
Dabigatran etexilate—Skin disorder—Epirubicin—uterine cancer	0.000229	0.000792	CcSEcCtD
Dabigatran etexilate—Arthralgia—Doxorubicin—uterine cancer	0.000228	0.000787	CcSEcCtD
Dabigatran etexilate—Chest pain—Doxorubicin—uterine cancer	0.000228	0.000787	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000226	0.000782	CcSEcCtD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—FGFR2—uterine cancer	0.000226	0.00455	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EP300—uterine cancer	0.000224	0.00451	CbGpPWpGaD
Dabigatran etexilate—Hypotension—Epirubicin—uterine cancer	0.000221	0.000762	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Doxorubicin—uterine cancer	0.000219	0.000755	CcSEcCtD
Dabigatran etexilate—Infection—Doxorubicin—uterine cancer	0.000217	0.00075	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000215	0.000743	CcSEcCtD
Dabigatran etexilate—Shock—Doxorubicin—uterine cancer	0.000215	0.000742	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Doxorubicin—uterine cancer	0.000214	0.00074	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Doxorubicin—uterine cancer	0.000214	0.000739	CcSEcCtD
Dabigatran etexilate—Skin disorder—Doxorubicin—uterine cancer	0.000212	0.000733	CcSEcCtD
Dabigatran etexilate—F2—Platelet Aggregation (Plug Formation)—AKT1—uterine cancer	0.000212	0.00428	CbGpPWpGaD
Dabigatran etexilate—Dyspnoea—Epirubicin—uterine cancer	0.000211	0.000727	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Epirubicin—uterine cancer	0.000208	0.000718	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—STAR—uterine cancer	0.000205	0.00413	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—AKR1B1—uterine cancer	0.000205	0.00413	CbGpPWpGaD
Dabigatran etexilate—Hypotension—Doxorubicin—uterine cancer	0.000204	0.000705	CcSEcCtD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—PIK3CA—uterine cancer	0.000204	0.00411	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000204	0.000704	CcSEcCtD
Dabigatran etexilate—Fatigue—Epirubicin—uterine cancer	0.000204	0.000703	CcSEcCtD
Dabigatran etexilate—Constipation—Epirubicin—uterine cancer	0.000202	0.000697	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000199	0.000687	CcSEcCtD
Dabigatran etexilate—UGT1A9—Biological oxidations—CYP19A1—uterine cancer	0.000195	0.00394	CbGpPWpGaD
Dabigatran etexilate—Dyspnoea—Doxorubicin—uterine cancer	0.000195	0.000673	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Epirubicin—uterine cancer	0.000193	0.000667	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metapathway biotransformation—CYP19A1—uterine cancer	0.000193	0.00388	CbGpPWpGaD
Dabigatran etexilate—Dyspepsia—Doxorubicin—uterine cancer	0.000192	0.000664	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000189	0.000651	CcSEcCtD
Dabigatran etexilate—Fatigue—Doxorubicin—uterine cancer	0.000188	0.00065	CcSEcCtD
Dabigatran etexilate—Urticaria—Epirubicin—uterine cancer	0.000188	0.000648	CcSEcCtD
Dabigatran etexilate—Constipation—Doxorubicin—uterine cancer	0.000187	0.000645	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Epirubicin—uterine cancer	0.000187	0.000645	CcSEcCtD
Dabigatran etexilate—F2—FOXA2 and FOXA3 transcription factor networks—AKT1—uterine cancer	0.000185	0.00372	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000179	0.000617	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Epirubicin—uterine cancer	0.000174	0.000601	CcSEcCtD
Dabigatran etexilate—Urticaria—Doxorubicin—uterine cancer	0.000174	0.000599	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Doxorubicin—uterine cancer	0.000173	0.000596	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.00017	0.00343	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.00017	0.00343	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Epirubicin—uterine cancer	0.000169	0.000585	CcSEcCtD
Dabigatran etexilate—Pruritus—Epirubicin—uterine cancer	0.000167	0.000577	CcSEcCtD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—AKT1—uterine cancer	0.000167	0.00336	CbGpPWpGaD
Dabigatran etexilate—Diarrhoea—Epirubicin—uterine cancer	0.000162	0.000558	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Doxorubicin—uterine cancer	0.000161	0.000556	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—POLD1—uterine cancer	0.000161	0.00324	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—INHBA—uterine cancer	0.000158	0.00319	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—TP53—uterine cancer	0.000158	0.00319	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—SMAD3—uterine cancer	0.000158	0.00318	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Doxorubicin—uterine cancer	0.000157	0.000541	CcSEcCtD
Dabigatran etexilate—Dizziness—Epirubicin—uterine cancer	0.000156	0.000539	CcSEcCtD
Dabigatran etexilate—Pruritus—Doxorubicin—uterine cancer	0.000155	0.000534	CcSEcCtD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	0.000152	0.00307	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—AKR1C1—uterine cancer	0.00015	0.00303	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Epirubicin—uterine cancer	0.00015	0.000518	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Doxorubicin—uterine cancer	0.00015	0.000516	CcSEcCtD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—NRAS—uterine cancer	0.000149	0.00301	CbGpPWpGaD
Dabigatran etexilate—Rash—Epirubicin—uterine cancer	0.000149	0.000514	CcSEcCtD
Dabigatran etexilate—Dermatitis—Epirubicin—uterine cancer	0.000149	0.000514	CcSEcCtD
Dabigatran etexilate—F2—Metabolism of proteins—MME—uterine cancer	0.000149	0.003	CbGpPWpGaD
Dabigatran etexilate—Headache—Epirubicin—uterine cancer	0.000148	0.000511	CcSEcCtD
Dabigatran etexilate—Dizziness—Doxorubicin—uterine cancer	0.000145	0.000499	CcSEcCtD
Dabigatran etexilate—Nausea—Epirubicin—uterine cancer	0.00014	0.000484	CcSEcCtD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—CCL2—uterine cancer	0.00014	0.00282	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Doxorubicin—uterine cancer	0.000139	0.00048	CcSEcCtD
Dabigatran etexilate—F2—Hemostasis—IRF1—uterine cancer	0.000139	0.0028	CbGpPWpGaD
Dabigatran etexilate—Rash—Doxorubicin—uterine cancer	0.000138	0.000476	CcSEcCtD
Dabigatran etexilate—Dermatitis—Doxorubicin—uterine cancer	0.000138	0.000475	CcSEcCtD
Dabigatran etexilate—Headache—Doxorubicin—uterine cancer	0.000137	0.000473	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—RRM2—uterine cancer	0.000134	0.0027	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—DCN—uterine cancer	0.00013	0.00262	CbGpPWpGaD
Dabigatran etexilate—Nausea—Doxorubicin—uterine cancer	0.00013	0.000448	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metabolism—NDUFB11—uterine cancer	0.000129	0.0026	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—SRD5A2—uterine cancer	0.000129	0.0026	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—KRAS—uterine cancer	0.000129	0.00259	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	0.000125	0.00252	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CYP11A1—uterine cancer	0.000123	0.00247	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—PIK3CA—uterine cancer	0.000118	0.00238	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—AKR1C3—uterine cancer	0.000116	0.00233	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—PPARA activates gene expression—EP300—uterine cancer	0.000111	0.00224	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—uterine cancer	0.000111	0.00224	CbGpPWpGaD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—CXCL8—uterine cancer	0.000111	0.00223	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—HRAS—uterine cancer	0.000109	0.0022	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—uterine cancer	0.000109	0.0022	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—NRAS—uterine cancer	0.000108	0.00217	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—SRD5A2—uterine cancer	0.000105	0.00211	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—NDUFB11—uterine cancer	0.000105	0.00211	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	0.000102	0.00205	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	9.78e-05	0.00197	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—FBXW7—uterine cancer	9.78e-05	0.00197	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	9.62e-05	0.00194	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	9.38e-05	0.00189	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—STAR—uterine cancer	9.33e-05	0.00188	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—AKR1B1—uterine cancer	9.33e-05	0.00188	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—KRAS—uterine cancer	9.27e-05	0.00187	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	9.07e-05	0.00183	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—STK11—uterine cancer	9.02e-05	0.00182	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CYP19A1—uterine cancer	9.02e-05	0.00182	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—AKR1B10—uterine cancer	9e-05	0.00181	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—PIK3CA—uterine cancer	8.52e-05	0.00172	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	8.23e-05	0.00166	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—uterine cancer	8.04e-05	0.00162	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—VEGFA—uterine cancer	7.96e-05	0.0016	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—CXCL8—uterine cancer	7.76e-05	0.00156	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—EP300—uterine cancer	7.68e-05	0.00155	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—AKR1B1—uterine cancer	7.58e-05	0.00153	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—STAR—uterine cancer	7.58e-05	0.00153	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—uterine cancer	7.5e-05	0.00151	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	7.5e-05	0.00151	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—RNF43—uterine cancer	7.46e-05	0.0015	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—ABCC9—uterine cancer	7.43e-05	0.0015	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	7.42e-05	0.0015	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	7.38e-05	0.00149	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—POLD1—uterine cancer	7.32e-05	0.00148	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—VEGFA—uterine cancer	7.27e-05	0.00147	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CCL2—uterine cancer	7.14e-05	0.00144	CbGpPWpGaD
Dabigatran etexilate—F2—G alpha (q) signalling events—PIK3CA—uterine cancer	7.1e-05	0.00143	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—uterine cancer	6.92e-05	0.00139	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—AKR1C1—uterine cancer	6.85e-05	0.00138	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—INHBA—uterine cancer	6.82e-05	0.00138	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—MTHFR—uterine cancer	6.78e-05	0.00137	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—uterine cancer	6.35e-05	0.00128	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—VEGFA—uterine cancer	6.3e-05	0.00127	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	6.22e-05	0.00125	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—AKR1C1—uterine cancer	6.14e-05	0.00124	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—RRM2—uterine cancer	6.1e-05	0.00123	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—POLD1—uterine cancer	5.95e-05	0.0012	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—DCN—uterine cancer	5.93e-05	0.00119	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—uterine cancer	5.88e-05	0.00119	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CXCL8—uterine cancer	5.65e-05	0.00114	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CYP11A1—uterine cancer	5.58e-05	0.00113	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—AKR1C1—uterine cancer	5.57e-05	0.00112	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	5.5e-05	0.00111	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—AKR1C3—uterine cancer	5.27e-05	0.00106	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—AKT1—uterine cancer	5.08e-05	0.00102	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—CCL2—uterine cancer	5.03e-05	0.00101	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—RRM2—uterine cancer	4.96e-05	0.001	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—DCN—uterine cancer	4.82e-05	0.000971	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SRD5A2—uterine cancer	4.81e-05	0.00097	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NDUFB11—uterine cancer	4.81e-05	0.00097	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—AKR1C3—uterine cancer	4.73e-05	0.000953	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—AKT1—uterine cancer	4.64e-05	0.000936	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PGR—uterine cancer	4.61e-05	0.000929	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYP11A1—uterine cancer	4.54e-05	0.000915	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—YWHAE—uterine cancer	4.39e-05	0.000886	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—EP300—uterine cancer	4.33e-05	0.000873	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—AKR1C3—uterine cancer	4.28e-05	0.000864	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FBXW7—uterine cancer	4.21e-05	0.00085	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—STK11—uterine cancer	4.11e-05	0.000828	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CYP19A1—uterine cancer	4.11e-05	0.000828	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—VEGFA—uterine cancer	4.1e-05	0.000827	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—NRAS—uterine cancer	4.05e-05	0.000817	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	4.04e-05	0.000814	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—CXCL8—uterine cancer	3.97e-05	0.000801	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PTEN—uterine cancer	3.77e-05	0.00076	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	3.74e-05	0.000754	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—STK11—uterine cancer	3.68e-05	0.000743	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CCL2—uterine cancer	3.67e-05	0.000739	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—CTNNB1—uterine cancer	3.67e-05	0.000739	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—EP300—uterine cancer	3.6e-05	0.000725	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	3.53e-05	0.000712	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—KRAS—uterine cancer	3.49e-05	0.000703	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—STAR—uterine cancer	3.48e-05	0.000701	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—AKR1B1—uterine cancer	3.48e-05	0.000701	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SOCS3—uterine cancer	3.45e-05	0.000695	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	3.44e-05	0.000694	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYP19A1—uterine cancer	3.34e-05	0.000673	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—STK11—uterine cancer	3.34e-05	0.000673	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CDKN2B—uterine cancer	3.3e-05	0.000666	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	3.28e-05	0.000662	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IGF1R—uterine cancer	3.21e-05	0.000646	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PIK3CA—uterine cancer	3.2e-05	0.000646	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CXCL8—uterine cancer	3.19e-05	0.000644	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	3.13e-05	0.000632	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	3.11e-05	0.000627	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TP53—uterine cancer	3.1e-05	0.000625	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—MTHFR—uterine cancer	3.09e-05	0.000622	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SMAD3—uterine cancer	3.01e-05	0.000608	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.99e-05	0.000602	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—HRAS—uterine cancer	2.96e-05	0.000598	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CXCL8—uterine cancer	2.9e-05	0.000584	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FGFR2—uterine cancer	2.88e-05	0.00058	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—POLD1—uterine cancer	2.73e-05	0.00055	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PIK3CA—uterine cancer	2.66e-05	0.000536	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	2.64e-05	0.000533	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—AKT1—uterine cancer	2.62e-05	0.000528	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—AKR1C1—uterine cancer	2.55e-05	0.000515	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—MTHFR—uterine cancer	2.51e-05	0.000506	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ESR1—uterine cancer	2.46e-05	0.000496	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	2.43e-05	0.00049	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	2.35e-05	0.000474	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—NRAS—uterine cancer	2.33e-05	0.000469	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—RRM2—uterine cancer	2.28e-05	0.000459	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.21e-05	0.000446	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—DCN—uterine cancer	2.21e-05	0.000445	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—AKT1—uterine cancer	2.17e-05	0.000438	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCL2—uterine cancer	2.17e-05	0.000437	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP11A1—uterine cancer	2.08e-05	0.00042	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CA—uterine cancer	2.02e-05	0.000408	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—KRAS—uterine cancer	2e-05	0.000403	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	1.98e-05	0.0004	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—AKR1C3—uterine cancer	1.97e-05	0.000396	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CA—uterine cancer	1.84e-05	0.000371	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ERBB2—uterine cancer	1.81e-05	0.000364	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PTEN—uterine cancer	1.72e-05	0.000346	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CXCL8—uterine cancer	1.71e-05	0.000345	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—HRAS—uterine cancer	1.7e-05	0.000343	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CDKN1B—uterine cancer	1.67e-05	0.000337	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—AKT1—uterine cancer	1.65e-05	0.000333	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—EP300—uterine cancer	1.64e-05	0.00033	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CTNNB1—uterine cancer	1.58e-05	0.000318	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTEN—uterine cancer	1.54e-05	0.00031	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—STK11—uterine cancer	1.53e-05	0.000309	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP19A1—uterine cancer	1.53e-05	0.000309	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—AKT1—uterine cancer	1.5e-05	0.000303	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EP300—uterine cancer	1.47e-05	0.000296	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PTEN—uterine cancer	1.4e-05	0.000281	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—VEGFA—uterine cancer	1.39e-05	0.00028	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NRAS—uterine cancer	1.37e-05	0.000277	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—EP300—uterine cancer	1.33e-05	0.000268	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CA—uterine cancer	1.21e-05	0.000244	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KRAS—uterine cancer	1.18e-05	0.000238	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—MTHFR—uterine cancer	1.15e-05	0.000232	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CA—uterine cancer	1.09e-05	0.000219	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TP53—uterine cancer	1.05e-05	0.000212	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HRAS—uterine cancer	1e-05	0.000203	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—AKT1—uterine cancer	9.9e-06	0.0002	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CA—uterine cancer	9.84e-06	0.000198	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—AKT1—uterine cancer	8.87e-06	0.000179	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—AKT1—uterine cancer	8.04e-06	0.000162	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PTEN—uterine cancer	6.4e-06	0.000129	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—EP300—uterine cancer	6.1e-06	0.000123	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CA—uterine cancer	4.52e-06	9.11e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—AKT1—uterine cancer	3.69e-06	7.44e-05	CbGpPWpGaD
